… heparin) are losing market exclusivity worldwide, inviting the generic/biosimilar drug … (GAG)
of animal origin having weight-average molecular weight (M w ) of ~ 12,000 Da …

… highly purified heparin lyase of bacterial origin., Heparin lyase … Recently, various patents for
low molecular weight heparin … , leading to generic or biosimilar products that capture market …

… Background Enoxaparin is the most widely used low molecular weight heparin (LMWH)
worldwide. Several biosimilar versions of Lovenox (enoxaparin sodium; Sanofi, Paris, France), …

… are developed by complex biological background. There are … drug and biosimilar.[8] Approval
of enoxaparin in July 2010, which is a generic heparin drug with low molecular weight, this …

… of heparin preparations, as well as identify the tissue of origin. … followed for low-molecular-weight
heparins, which we … of low-molecular-weight heparin for molecular weight calibration”. …

… Generics are chemically synthesized small molecules, which … is then possible to determine
the molecular mass accurately. If we … , we can achieve 100% coverage of the sequence. This …

… of high molecular weight with high complexity and are … Formulary and, when this is not
mentioned, that period should … some biosimilars, such as low-molecular-weight heparins obtained …

… number and the country of origin may be used for distinction. … coverage in favor of biosimilars
counterparts ▪ Subjecting … , FDA had approved low molecular weight heparin – Levonox- …

… as well as wholesale price in the country of origin in its local currency; 5) the proposed …
drug evaluation is necessary prior to addition. The process of biosimilar addition to a formulary …

… biosimilars are relatively recent additions to the formulary. … The first difference is size: for
example, the molecular mass of … of small molecule drugs drove down prices, biosimilars can …